32 years @Pfizer. #Hematology Opinion Leader Liaison, passionately helping to better lives of patients with blood cancer. My opinions are my own. #PFEColleague
Chicago, IL
Joined October 2015
- Tweets138
- Following237
- Followers109
- Likes355
Daniel Harter retweeted
#ASH25 US Multiple Myeloma Immunotherapy consortium
We presented 14 orals, 8 posters at ASH!
Now with 25+ sites
Could never have imagined this success when Dr Hansen, Patel and I co-founded this 4+ years ago.
Incredible collaborative effort!! A lot of work goes into this.
Excited to be at #ASH25 where Pfizer is sharing 20+ abstracts in blood cancer across #multiplemyeloma, #leukemia & #lymphoma. Visit booth #1843 to see how we’re advancing science in hematologic malignancies and working to improve outcomes for patients.
2
76
Daniel Harter retweeted
WATCH: Binod Dhakal, MD, explores innovative bridging therapies for multiple myeloma, enhancing patient outcomes before CAR T-cell treatment while addressing significant challenges. Check out the full interview: hubs.li/Q03DJbPs0
Daniel Harter retweeted
Explore the latest findings from Pfizer Oncology in our poster presentations at #ASCO25. See the full program here: bit.ly/4jYYOJE
Daniel Harter retweeted
I love talking to current and former patients.
They keep us grounded, humbled, and remind us why we do what we do and how we can do better.
Today’s #HealthcareUnfiltered is ALL about that as Carol Rausch shares her story.
A must listen for all.
podcasts.apple.com/us/podcas…
Daniel Harter retweeted
#weekend_review
#MedTwitter #hemonctrainees
1/ Focusing on "chemo-free" regimen for "Ph-ve" B-cell ALL
1. Blinatumomab is better induction or Inotuzumab ozogamicin?
2. Response rate with chemo-free regimen in high risk ALL?
3. Should we intensify CNS prophylaxis with "chemo-free" regimen?👇
Daniel Harter retweeted
Cellular Therapies and Novel Targeted Agents Will Shape the Future of R/R #ALL Management @LuskinMarlise @DanaFarber
onclive.com/cellular-therapi…
Change the Odds with Patrick Dempsey and the American Cancer Society #PFEColleague bit.ly/4emf841
3
58
By continuing to accelerate advancements in the treatment of #BloodCancer, we’re working to create a world where people with cancer live better and longer lives.. #BloodCancerAwarenessMonth #PFEColleague bit.ly/3z9Pnp3
2
29
Daniel Harter retweeted
Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring doi.org/10.1002/ajh.27443
#CML #LeuSM
Daniel Harter retweeted
phase Ib/II study of sonrotoclax and dex in RRMM with t (11;14)- ORR 75% at 640 mg with ~70% triple class ref pts! Impressive safety profile with no DLT @EHA_Hematology @MCWCancerCenter #EHA24
Pfizer on LinkedIn: Hispanic and Latino communities represent 19% of the national population… #PFEColleague bit.ly/3xF2CwR
29
Daniel Harter retweeted
Looking forward to serving with such an incredible group on the @HOPArx board!
We are all motivated by our commitment to our patients, team and profession. We like to 😂 too!!
#oncopharm
Come say hi! #HOPA2024
As we recognize International Women’s Day (IWD) and Women’s History Month (WHM), I’m committed to #InspiringInclusion. I’m #PfizerProud to work at a company that values, respects, and includes all people, no matter our backgrounds. #IWD2024 #PFEColleague bit.ly/3IrAek3
2
40
A special message of appreciation to the CML patients and families, and gratitude to the research and health care teams who have impacted this disease. #CML #WorldCMLday #PFEColleague bit.ly/3Zrf8cW
2
66